Susquehanna International Group
CUE icon

Susquehanna International Group’s Cue Biopharma CUE Stock Holding History

Susquehanna International Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,093
Closed -$62K – 12186
2024
Q1 		$62K Buy
1,093
+236
+28% +$16.6K ﹤0.01% 11470
2023
Q4 		$67.8K Buy
857
+70
+9% +$5K ﹤0.01% 11569
2023
Q3 		$54.3K Buy
+787
New +$76.8K ﹤0.01% 11264
2022
Q2 		– Sell
-1,897
Closed -$278K – 13033
2022
Q1 		$278K Buy
1,897
+390
+26% +$82.7K ﹤0.01% 10452
2021
Q4 		$511K Buy
1,507
+350
+30% +$135K ﹤0.01% 9143
2021
Q3 		$506K Sell
1,157
-1,076
-48% -$375K ﹤0.01% 9372
2021
Q2 		$781K Sell
2,233
-630
-22% -$244K ﹤0.01% 8444
2021
Q1 		$1.05M Buy
2,863
+853
+42% +$351K ﹤0.01% 7615
2020
Q4 		$754K Buy
2,010
+1,007
+100% +$402K ﹤0.01% 7355
2020
Q3 		$453K Sell
1,003
-1,070
-52% -$617K ﹤0.01% 7876
2020
Q2 		$1.52M Buy
2,073
+1,300
+168% +$942K ﹤0.01% 4999
2020
Q1 		$329K Buy
+773
New +$375K ﹤0.01% 7800

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Susquehanna International Group's CUE Position: Q1 2026 in Review

Susquehanna International Group reduced its Cue Biopharma (CUE) stake by 85% in Q1 2026, selling an estimated $44.9K and leaving 820 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #12979.

Susquehanna International Group first reported a position in CUE in Q2 2020 and has held it in 21 quarters since. The position peaked at $689K in Q1 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Susquehanna International Group held 820 shares of Cue Biopharma worth $5.66K as of Q1 2026.
  • Susquehanna International Group sold 4,808 Cue Biopharma shares in Q1 2026, an estimated $44.9K.
  • Cue Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12979 holding.
  • Susquehanna International Group first reported a position in Cue Biopharma in Q2 2020 and has held it in 21 quarters since.
  • Susquehanna International Group's Cue Biopharma position peaked at $689K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.